Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

被引：8
|
作者：
Doshi, Bhavya S. [1 ,2 ]
Witmer, Char M. [1 ,2 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3501 Civ Ctr Blvd,CTRB 5024, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 04期
关键词：
emicizumab; haemophilia A; immune tolerance; inhibitor; recurrence; IMMUNE TOLERANCE;
D O I：
10.1111/hae.14311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E551 / E553
页数：3
相关论文
共 50 条
  • [1] Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures
    Cooper, HA
    Jones, CP
    Campion, E
    Roberts, HR
    Hedner, U
    HAEMOPHILIA, 2001, 7 (05) : 517 - 522
  • [2] The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile
    Greninger, D. A.
    Saint-Remy, J. M.
    Jacquemin, M.
    Benhida, A.
    Dimichele, D. M.
    HAEMOPHILIA, 2008, 14 (02) : 295 - 302
  • [3] A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations
    Li, Zekun
    Chen, Zhenping
    Cheng, Xiaoling
    Wu, Xinyi
    Li, Gang
    Zhen, Yingzi
    Poon, Man-Chiu
    Wu, Runhui
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2020, 34
  • [4] Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages
    Moonla, Chatphatai
    Uaprasert, Noppacharn
    Watanaboonyongcharoen, Phandee
    Meesanun, Mukmanee
    Sukperm, Autcharaporn
    Jantasing, Ratchaneekorn
    Faknuam, Saruta
    Chanswangphuwana, Chantiya
    Polprasert, Chantana
    Sodsai, Pimpayao
    Akkawat, Benjaporn
    Hirankarn, Nattiya
    Bunworasate, Udomsak
    Rojnuckarin, Ponlapat
    HAEMOPHILIA, 2021, 27 (01) : E155 - E159
  • [5] Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa
    Sheth, S
    DiMichele, D
    Lee, M
    Lamour, J
    Quaegebeur, J
    Hsu, D
    Addonizio, L
    Piomelli, S
    HAEMOPHILIA, 2001, 7 (02) : 227 - 232
  • [6] Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
    Kurth, M. A. H.
    Dimichele, D.
    Sexauer, C.
    Sanders, J. M.
    Torres, M.
    Zappa, S. C.
    Ragni, M.
    Leonard, N.
    HAEMOPHILIA, 2008, 14 (01) : 50 - 55
  • [7] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [8] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Shimonishi, Naruto
    Sasai, Kana
    Ogiwara, Kenichi
    Furukawa, Shoko
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Yada, Koji
    Takeyama, Masahiro
    Shima, Midori
    Mizuno, Narumi
    Nogami, Keiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (06) : 690 - 698
  • [9] Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high-inhibitor titres
    Tamura, K
    Kanazawa, T
    Suzuki, M
    Shioya, A
    Morikawa, A
    HAEMOPHILIA, 2006, 12 (01) : 100 - 102
  • [10] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Naruto Shimonishi
    Kana Sasai
    Kenichi Ogiwara
    Shoko Furukawa
    Yuto Nakajima
    Kuniyoshi Mizumachi
    Koji Yada
    Masahiro Takeyama
    Midori Shima
    Narumi Mizuno
    Keiji Nogami
    International Journal of Hematology, 2023, 118 : 690 - 698
12345